Related Experiment Videos
[Prostaglandin E-2 in cyanotic heart defects in newborn (author's transl)]
Insights
Prostaglandin E2 infusions effectively improved oxygenation in newborn infants with critical heart conditions like transposition of the great arteries (TGA) and pulmonary atresia. Early treatment with PGE2 infusions offers significant benefits for these neonates awaiting interventions.
Area of Science:
- Neonatal cardiology
- Pediatric pharmacology
- Congenital heart disease
Context:
- Pulmonary atresia and transposition of the great arteries (TGA) are severe congenital heart defects requiring immediate intervention.
- Hypoxia and acidosis are critical complications in neonates with these conditions.
- Prostaglandin E2 (PGE2) is a vasodilator that can maintain ductal patency, crucial for systemic blood flow.
Purpose:
- To evaluate the efficacy and safety of Prostaglandin E2 infusions in neonates with pulmonary atresia or TGA.
- To assess the impact of PGE2 on oxygenation (paO2) and acid-base balance.
- To determine the optimal timing and duration of PGE2 infusions in this patient population.
Summary:
- 14 newborns with pulmonary atresia or TGA received PGE2 infusions to manage hypoxia and acidosis.
- 12 patients received infusions before diagnostic catheterization and balloon atrioseptostomy.
- PGE2 infusions led to a significant increase in paO2 in most patients, particularly when initiated within the first four days of life.
- While side effects were observed in two-thirds of cases, PGE2 was deemed safe and effective for improving oxygenation, even in the absence of adequate interatrial communication.
Impact:
- PGE2 infusions can be safely administered to neonates with TGA awaiting catheterization, improving oxygenation by maintaining ductal patency.
- Early initiation of PGE2 therapy is associated with better outcomes.
- Understanding potential side effects like congestive heart failure due to prolonged ductal patency is crucial for patient management.
Abstract:
14 newborn babies with pulmonary atresia (4) or transposition (TGA) (8) received Prostaglandin E2 infusions to correct their hypoxia and acidosis. 12 out of 10 patients were infused before diagnostic catheterization and creation of an interatrial communication by balloon atrioseptostomy. Infusions were stopped after septostomy in patients with transposition and prolonged up to palliative surgery in pulmonary atresia patients. All patients whose treatment was started in the first four days of life had a highly significant rise of their paO2. The only non-responder was a patient with TGA after septostomy who was a non-mixer and seven days old. Typical side effects of PGE2 were seen in two-thirds of all cases. One patient with TGA needed ductus ligation after PGE2 withdrawal because of congestive heart failure due to prolonged ductus patency. We conclude that prostaglandins of the E-type can safely be used in all cases of TGA with hypoxia and acidosis who are awaiting catheterization. Even when an adequate interatrial communication does not yet exist PGE2 seems to bring good oxygenation by opening the ductus. Used up to a maximum of 32 hours infusion-time heart failure was not seen.